sildenafil vs Tadalafil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: PDE5 · full Pulmonary Arterial Hypertension pipeline
sildenafil · Revatio
Marketed by Viatris and partners
NCT00644605 · Phase 3 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: April 2028 · NCT07824674 (registry estimate)
Reported efficacy
Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test). (Week 12): The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). (met)
Result source: NCT00644605
Tadalafil · Adcirca
Marketed by Eli Lilly and partners
NCT00549302 · Phase 3 · completed
This trial continued participants who had already been randomized in an earlier placebo-controlled study rather than randomizing a new population, and its own primary outcome was a pooled safety tally without a placebo comparator, so it provides supportive long-term evidence rather than a fresh controlled demonstration of efficacy. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: May 2028 · NCT06968962 (registry estimate)
Reported efficacy
Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters (Baseline, Week 24): 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) (missed)
Result source: NCT01824290
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. sildenafil: 7 of 7 rows · Tadalafil: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | sildenafil Rows use multiple source trials | Tadalafil Rows use multiple source trials |
|---|---|---|
| 6MWD - Change absolute change · m No placebo or comparator arm | 84.2 m @ 12wka,b,c,d,e NCT00454207 · Phase 3 · registry result, not featured evidence show 1 more dose-23.5 m @ 12wk NCT00454207 · Phase 3 · registry result, not featured evidence | 395 m @ 36wkb,c,d,e NCT01042158 · Phase 4 · registry result, not featured evidence · combination |
| Borg Dyspnea absolute change · score No placebo or comparator arm | 0 score @ 24wkc NCT00159861 · Phase 3 | -1 score @ 24wka,c NCT01178073 · Phase 3 · registry result, not featured evidence · combination show 1 more dose-0.5 score @ 24wk NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy |
| PVR absolute change · Wood units No placebo or comparator arm | -6.145 Wood units @ 16wkc,d,f NCT01642407 · Phase 4 · registry result, not featured evidence | 3.1 Wood units @ 36wkc,d,f NCT01042158 · Phase 4 · registry result, not featured evidence · combination |
| Dropout rate | —g NCT00159861 · Phase 3 show 17 more results2.6%High Dose NCT00159913 · Phase 3 4.8%Low Dose NCT00159913 · Phase 3 0%Medium Dose NCT00159913 · Phase 3 52.2%high dose NCT00159874 · Phase 3 46.2%low dose NCT00159874 · Phase 3 42.1%medium dose NCT00159874 · Phase 3 —high dose NCT00159874 · Phase 3 55.8%high dose NCT00159874 · Phase 3 —low dose NCT00159874 · Phase 3 47.6%low dose NCT00159874 · Phase 3 —medium dose NCT00159874 · Phase 3 54.5%medium dose NCT00159874 · Phase 3 14% NCT00323297 · Phase 4 50% NCT01642407 · Phase 4 · registry result, not featured evidence —400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination —200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination — NCT00454207 · Phase 3 · registry result, not featured evidence | 18%40 mgg NCT00549302 · Phase 3 show 7 more results4% NCT01042158 · Phase 4 · registry result, not featured evidence · combination 20.5%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · registry result, not featured evidence · combination 30.5%Tadalafil Monotherapy NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy 0%Heavy Weight: ≥40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence 0%Light Weight <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Light Weight: <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence 0%Middle Weight: 25 kg to <40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —g NCT00159861 · Phase 3 show 17 more results1.3%High Dose NCT00159913 · Phase 3 2.4%Low Dose NCT00159913 · Phase 3 0%Medium Dose NCT00159913 · Phase 3 8.7%high dose NCT00159874 · Phase 3 7.7%low dose NCT00159874 · Phase 3 5.3%medium dose NCT00159874 · Phase 3 —high dose NCT00159874 · Phase 3 6.5%high dose NCT00159874 · Phase 3 —low dose NCT00159874 · Phase 3 4.8%low dose NCT00159874 · Phase 3 —medium dose NCT00159874 · Phase 3 3.6%medium dose NCT00159874 · Phase 3 4% NCT00323297 · Phase 4 — NCT01642407 · Phase 4 · registry result, not featured evidence —400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination —200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination — NCT00454207 · Phase 3 · registry result, not featured evidence | 5.4%40 mgg NCT00549302 · Phase 3 show 7 more results— NCT01042158 · Phase 4 · registry result, not featured evidence · combination 11.3%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · registry result, not featured evidence · combination 15.9%Tadalafil Monotherapy NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy —Heavy Weight: ≥40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Light Weight <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Light Weight: <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Middle Weight: 25 kg to <40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 77.6%g NCT00159861 · Phase 3 show 17 more results—High Dose NCT00159913 · Phase 3 —Low Dose NCT00159913 · Phase 3 —Medium Dose NCT00159913 · Phase 3 —high dose NCT00159874 · Phase 3 —low dose NCT00159874 · Phase 3 —medium dose NCT00159874 · Phase 3 48%high dose NCT00159874 · Phase 3 —high dose NCT00159874 · Phase 3 25.5%low dose NCT00159874 · Phase 3 —low dose NCT00159874 · Phase 3 50%medium dose NCT00159874 · Phase 3 —medium dose NCT00159874 · Phase 3 44% NCT00323297 · Phase 4 0% NCT01642407 · Phase 4 · registry result, not featured evidence 5.6%400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination 10.5%200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination 15.9% NCT00454207 · Phase 3 · registry result, not featured evidence | —40 mgg NCT00549302 · Phase 3 show 7 more results12.5% NCT01042158 · Phase 4 · registry result, not featured evidence · combination 41.1%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · registry result, not featured evidence · combination 45%Tadalafil Monotherapy NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy 50%Heavy Weight: ≥40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Light Weight <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence 16.7%Light Weight: <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence 57.1%Middle Weight: 25 kg to <40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | g headache 67.9% (placebo 18.8%) diarrhoea 47.8% (placebo 31.3%) nausea 47% (placebo 25%) NCT00159861 · Phase 3 show 11 more resultsHigh Dose headache 15.6% (placebo 13.3%) vomiting 14.3% (placebo 6.7%) pyrexia 10.4% (placebo 1.7%) NCT00159913 · Phase 3 Low Dose headache 11.9% (placebo 13.3%) upper respiratory tract infection 9.5% (placebo 6.7%) nasopharyngitis 7.1% (placebo 6.7%) NCT00159913 · Phase 3 Medium Dose pyrexia 14.5% (placebo 1.7%) upper respiratory tract infection 14.5% (placebo 6.7%) headache 10.9% (placebo 13.3%) NCT00159913 · Phase 3 medium dose upper respiratory tract infection 29.7% headache 24.3% bronchitis 21.6% NCT00159874 · Phase 3 diarrhoea 14% (placebo 9.4%) headache 14% (placebo 13.2%) oedema peripheral 14% (placebo 15.1%) NCT00323297 · Phase 4 bronchitis 50% nasopharyngitis 50% upper respiratory tract infection 50% NCT01642407 · Phase 4 · registry result, not featured evidence 400 mg/Day vomiting 22.2% anaemia 16.7% blood potassium decreased 16.7% NCT01392469 · Phase 3 · registry result, not featured evidence · combination 200 mg/Day diarrhoea 26.3% nausea 21.1% back pain 10.5% NCT01392469 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 38.6% headache 25% flushing 22.7% NCT00454207 · Phase 3 · registry result, not featured evidence | g oedema peripheral 44% headache 41.1% diarrhoea 20.9% NCT01178073 · Phase 3 · registry result, not featured evidence · combination show 4 more resultsheadache 36.4% oedema peripheral 29.1% dyspnoea 18.5% NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy angina pectoris 33.3% ear pain 33.3% headache 33.3% NCT01484431 · Phase 1/2 · registry result, not featured evidence gastroenteritis 50% bronchitis 33.3% ecchymosis 33.3% NCT01484431 · Phase 1/2 · registry result, not featured evidence oropharyngeal pain 42.9% headache 28.6% pain in extremity 28.6% NCT01484431 · Phase 1/2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 4.
- cPopulation context differs: registered conditions differ.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 12 weeks versus 36 weeks.
- fAssessment timepoints differ: 16 weeks versus 36 weeks.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
sildenafil
show 2 more results
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 48 further endpoints in the CSV export.
Tadalafil
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: sildenafil's landscape · Tadalafil's landscape